LongBio Pharma says FDA clears LP-003 peanut allergy clinical trial application

• LongBio Pharma (Suzhou) won US FDA clearance for its clinical trial application for LP-003 in peanut allergy.
• LP-003 is an anti-IgE antibody candidate designed to block free IgE, aiming to prevent IgE-driven allergic reactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260713-12241994), on July 13, 2026, and is solely responsible for the information contained therein.